Compare
Gilead Sciences, Inc. vs Amgen Inc vs Neurocrine Biosciences Inc vs Exelixis, Inc.
| Latest fiscal year | Gilead Sciences, Inc. GILD | Amgen Inc AMGN | Neurocrine Biosciences Inc NBIX | Exelixis, Inc. EXEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-01-02 |
| Revenue | $29.44B | $36.75B | $2.86B | $2.32B |
| Revenue growth (YoY) | +2.4% | +10.0% | +21.4% | +7.0% |
| Gross margin | 78.8% (computed) | 67.2% (computed) | n/a | n/a |
| Operating margin | 34.0% | 24.7% | 21.6% | 37.6% |
| Net margin | 28.9% | 21.0% | 16.7% | 33.7% |
| Net income | $8.51B | $7.71B | $478.60M | $782.57M |
| EPS (Diluted) | $6.78 | $14.23 | $4.67 | $2.78 |
| Operating cash flow | $10.02B | $9.96B | $782.70M | $884.27M |
| Free cash flow | $9.46B | $8.10B | $748.70M | $875.84M |
| Cash & equivalents | n/a | $9.13B | $713.00M | $482.49M |
| Total assets | $59.02B | $90.59B | $4.63B | $2.84B |
| Total liabilities | n/a | n/a | $1.38B | $683.10M |
| Shareholders' equity | $22.62B | $8.66B | $3.25B | $2.16B |
| Return on year-end equity | 37.6% | 89.1% | 14.7% | 36.2% |
| Shares outstanding | 1.24B | 538.80M | 100.10M | 262.48M |
Revenue, most recent five fiscal years
| Fiscal year | Gilead Sciences, Inc. | Amgen Inc | Neurocrine Biosciences Inc | Exelixis, Inc. |
|---|---|---|---|---|
| Latest | $29.44B Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $2.86B Ended 2025-12-31 | $2.32B Ended 2026-01-02 |
| 1 year earlier | $28.75B Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $2.36B Ended 2024-12-31 | $2.17B Ended 2025-01-03 |
| 2 years earlier | $27.12B Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $1.83B Ended 2023-12-29 |
| 3 years earlier | $27.28B Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $1.49B Ended 2022-12-31 | $1.61B Ended 2022-12-30 |
| 4 years earlier | $27.30B Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $1.13B Ended 2021-12-31 | $1.43B Ended 2021-12-31 |